AIM: To examine the construct validity of generic preference-weighted health-related quality of life measures in a sample of patients with a substance use disorder (SUD). DESIGN: Longitudinal (baseline and 6-month follow-up) data from a research study that evaluated interventions to improve linkage and engagement with SUD treatment. SETTING: A central intake unit that referred patients to seven SUD treatment centers in a Midwestern US metropolitan area. PARTICIPANTS: A total of 495 individuals with a SUD. MEASUREMENTS: Participants completed two preference-weighted measures: the self-administered Quality of Well-Being scale (QWB-SA) and the standard gamble weighted Medical Outcomes Study SF-12 (SF-6D). They were also administered two clinical assessments: all seven domains of the Addiction Severity Index (ASI) and a symptom checklist based on the DSM-IV. Construct validity was determined via the relationships between disease-specific SUD and generic measures. FINDINGS: In unadjusted analyses, the QWB-SA and SF-6D change scores were correlated significantly with six ASI subscale change scores, but not with employment status. In adjusted repeated-measures analyses, three of seven ASI subscale scores were significant predictors of QWB-SA and 5/7 ASI subscale scores were significant predictors of SF-6D. Abstinence and problematic use at follow-up were significant predictors of QWB-SA and SF-6D. Effect sizes ranged from 0.352 to 0.400 for abstinence and -0.484 to -0.585 for problematic use. CONCLUSIONS: Generic preference-weighted health-related quality of life measures show moderate to good associations with substance-use specific measures and in certain circumstances can be used in their stead. This study provides further support for the use of the Quality of Well-Being scale and Medical Outcomes Study SF-12 in clinical and economic evaluations of substance use disorder interventions.
AIM: To examine the construct validity of generic preference-weighted health-related quality of life measures in a sample of patients with a substance use disorder (SUD). DESIGN: Longitudinal (baseline and 6-month follow-up) data from a research study that evaluated interventions to improve linkage and engagement with SUD treatment. SETTING: A central intake unit that referred patients to seven SUD treatment centers in a Midwestern US metropolitan area. PARTICIPANTS: A total of 495 individuals with a SUD. MEASUREMENTS: Participants completed two preference-weighted measures: the self-administered Quality of Well-Being scale (QWB-SA) and the standard gamble weighted Medical Outcomes Study SF-12 (SF-6D). They were also administered two clinical assessments: all seven domains of the Addiction Severity Index (ASI) and a symptom checklist based on the DSM-IV. Construct validity was determined via the relationships between disease-specific SUD and generic measures. FINDINGS: In unadjusted analyses, the QWB-SA and SF-6D change scores were correlated significantly with six ASI subscale change scores, but not with employment status. In adjusted repeated-measures analyses, three of seven ASI subscale scores were significant predictors of QWB-SA and 5/7 ASI subscale scores were significant predictors of SF-6D. Abstinence and problematic use at follow-up were significant predictors of QWB-SA and SF-6D. Effect sizes ranged from 0.352 to 0.400 for abstinence and -0.484 to -0.585 for problematic use. CONCLUSIONS: Generic preference-weighted health-related quality of life measures show moderate to good associations with substance-use specific measures and in certain circumstances can be used in their stead. This study provides further support for the use of the Quality of Well-Being scale and Medical Outcomes Study SF-12 in clinical and economic evaluations of substance use disorder interventions.
Authors: Emily C Williams; Tibor Palfai; Debbie M Cheng; Jeffrey H Samet; Katharine A Bradley; Thomas D Koepsell; Thomas M Wickizer; Patrick J Heagerty; Richard Saitz Journal: Alcohol Clin Exp Res Date: 2010-05-04 Impact factor: 3.455
Authors: Jeffrey M Pyne; William J Sieber; Kristin David; Robert M Kaplan; Mark Hyman Rapaport; D Keith Williams Journal: J Affect Disord Date: 2003-09 Impact factor: 4.839
Authors: Bruce R Schackman; Jared A Leff; Daniel Polsky; Brent A Moore; David A Fiellin Journal: J Gen Intern Med Date: 2012-01-04 Impact factor: 5.128
Authors: David Goodman-Meza; Steve Shoptaw; Robert E Weiss; Terry Nakazono; Nina T Harawa; Sae Takada; Wendy H Garland; William E Cunningham Journal: Drug Alcohol Depend Date: 2019-07-16 Impact factor: 4.492
Authors: S Schawo; C Bouwmans; E van der Schee; V Hendriks; W Brouwer; L Hakkaart Journal: Health Qual Life Outcomes Date: 2017-09-19 Impact factor: 3.186
Authors: Bente Birkeland; Kim Foster; Anne S Selbekk; Magnhild M Høie; Torleif Ruud; Bente Weimand Journal: Health Qual Life Outcomes Date: 2018-11-20 Impact factor: 3.186